Press releases
-
OSE Immunotherapeutics Announces Results of 2020 Virtual Combined General Meeting
16/06/2020DOWNLOAD -
OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy
10/06/2020DOWNLOAD -
OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology
09/06/2020DOWNLOAD -
OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting – Live Webcast Login Information
27/05/2020DOWNLOAD -
OSE Immunotherapeutics Signs €7 Million Non-Dilutive Loan Agreement Guaranteed by the French State
26/05/2020DOWNLOAD -
OSE Immunotherapeutics Presents CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy – Oral Presentation at AACR Virtual Meeting II 2020
18/05/2020DOWNLOAD -
OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program
05/05/2020DOWNLOAD -
Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer
01/04/2020DOWNLOAD -
OSE Immunotherapeutics Reports 2019 Financial Results and Provides Business Update – Expectations for Potential Impact of COVID-19 on the Company’s Clinical Development Activities
26/03/2020DOWNLOAD -
OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases
17/03/2020DOWNLOAD -
OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico
12/02/2020DOWNLOAD -
OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi® on Inducing Early T-Lymphocyte Memory Response
14/01/2020DOWNLOAD -
OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127
02/12/2019DOWNLOAD -
OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer
27/11/2019DOWNLOAD -
OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi® At the 34th SITC Annual Meeting
11/11/2019DOWNLOAD -
OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea with Chong Kun Dang Pharmaceutical Corporation
07/11/2019DOWNLOAD -
OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines To Overcome Tumor Resistance to Checkpoint Inhibitor Blockade
30/09/2019DOWNLOAD -
OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance for SIRPα-Antagonist Monoclonal Antibody BI 765063
18/09/2019DOWNLOAD -
OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update
05/09/2019DOWNLOAD -
OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703, a Cytotoxic Monoclonal Antibody Targeting IL-7R, in Cancer Patients
03/09/2019DOWNLOAD -
OSE Immunotherapeutics Receives a Grant from the French National Research Agency to Validate New Targets Linked to Myeloid Cells and Identify Innovative New Immunotherapies in Oncology
23/07/2019DOWNLOAD -
First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance in the American Journal of Transplantation
17/07/2019DOWNLOAD -
OSE Immunotherapeutics Receives Special Recognition for European Growth, Healthcare Enterprise and Women Entrepreneurship Awarded by Forbes, PME Finance – Europe Entrepreneurs and their Partners
10/07/2019DOWNLOAD -
OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting
26/06/2019DOWNLOAD -
OSE Immunotherapeutics will participate in HealthTech Investor Days (HTID), Event hosted by France Biotech on 24th & 25th June in Paris
24/06/2019DOWNLOAD -
Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation
20/06/2019DOWNLOAD -
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
17/06/2019DOWNLOAD -
OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Use of Tedopi® to Treat Brain Metastasis
11/06/2019DOWNLOAD -
OSE Immunotherapeutics to Present at 5th Annual Immuno-Oncology: BD&L and Investment Forum to be held in Chicago, IL, on May 31, 2019
28/05/2019DOWNLOAD -
OSE Immunotherapeutics to Host Key Opinion Leader Meeting on Novel Treatments in Non-Small Cell Lung Cancer – Meeting Scheduled for May 30, 2019 in New York City
22/05/2019DOWNLOAD -
OSE Immunotherapeutics Receives Notice of Allowance for New U.S. Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127
20/05/2019DOWNLOAD -
OSE Immunotherapeutics Announces Publication on Anti-IL-7 Receptor Antagonist, OSE-127, in The Journal of Clinical Investigation
11/04/2019DOWNLOAD -
OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104
09/04/2019DOWNLOAD -
OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019
02/04/2019DOWNLOAD -
OSE Immunotherapeutics Reports 2018 Financial Results and Business Update
28/03/2019DOWNLOAD -
OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center to Use Artificial Intelligence Technologies to Identify Novel Immuno-Oncology Targets
26/03/2019DOWNLOAD -
OSE Immunotherapeutics Presents its Novel Bispecific Checkpoint Inhibitor Platform, Targeting PD-1 and Innovative Targets
07/03/2019DOWNLOAD -
OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate Selective SIRPα antagonist BI 765063 under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors
05/03/2019DOWNLOAD -
OSE Immunotherapeutics to Present New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019, Oral presentation will highlight early signs of activity of Tedopi® from the ongoing Phase 3 trial in NSCLC
28/02/2019DOWNLOAD -
OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases
07/02/2019DOWNLOAD -
OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis
15/01/2019DOWNLOAD -
OSE Immunotherapeutics to present at Biotech Showcase™ 2019 Conference During JP Morgan Healthcare Conference San Francisco, January 7-9, 2019
03/01/2019DOWNLOAD -
OSE Immunotherapeutics Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of OSE-127
20/12/2018DOWNLOAD -
OSE Immunotherapeutics Appoints Julien Perrier Chief Commercial Officer
17/12/2018DOWNLOAD -
OSE Immunotherapeutics Invited to Present Mechanistic Data on Clinical Stage Anti-Interleukin-7 Receptor Antagonist OSE-127 at Two International Scientific Conferences
10/12/2018DOWNLOAD -
OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate Anti-IL-7 Receptor Antagonist OSE-127
26/11/2018DOWNLOAD -
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer
20/11/2018DOWNLOAD -
OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech
02/11/2018DOWNLOAD -
OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)
29/10/2018DOWNLOAD -
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of a Clinical Trial Application to Evaluate Tedopi® in Combination with Nivolumab in Pancreatic Cancer
10/10/2018DOWNLOAD -
OSE Immunotherapeutics to Present at the 18th Annual Biotech in Europe Investor Forum, Oct. 4-5, 2018, Congress Center Basel
01/10/2018DOWNLOAD -
OSE Immunotherapeutics Reports First-Half 2018 Results and Provides a Corporate Update
06/09/2018DOWNLOAD -
OSE Immunotherapeutics Publishes New Efficacy Data on FR104, CD28-Antagonist Immunotherapy
22/08/2018DOWNLOAD -
OSE Immunotherapeutics Announces Issuance of a European Patent Protecting FR104, CD28-Antagonist Immunotherapy
22/08/2018DOWNLOAD -
OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi®
05/07/2018DOWNLOAD -
OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®
02/07/2018DOWNLOAD -
OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting
13/06/2018DOWNLOAD -
OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum Forum to be held in Chicago, IL, on June 1, 2018
17/05/2018DOWNLOAD -
OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting
07/05/2018DOWNLOAD -
OSE Immunotherapeutics Receives the Euronext Tech40 Label
23/04/2018DOWNLOAD -
OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management
12/04/2018DOWNLOAD -
OSE Immunotherapeutics to Host Conference Call on April 5, 2018 to Discuss Boehringer Ingelheim Global Immuno-Oncology Partnership
05/04/2018DOWNLOAD -
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
04/04/2018DOWNLOAD -
OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products – Key Clinical Portfolio Development Progress Planned for 2018
28/03/2018DOWNLOAD -
OSE Immunotherapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
27/03/2018DOWNLOAD -
OSE Immunotherapeutics to Present New Data on OSE-172 at American Association for Cancer Research Annual Meeting 2018, Chicago, April 14-18
19/03/2018DOWNLOAD -
OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment – Phase 3 Trial received Approval to be Initiated in Israel
15/03/2018DOWNLOAD -
OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING®, Amsterdam, March 12-14, 2018
28/02/2018DOWNLOAD -
OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
27/02/2018DOWNLOAD -
OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Applications
25/01/2018DOWNLOAD -
OSE Immunotherapeutics to present at Biotech Showcase™ 2018 Conference
04/01/2018DOWNLOAD -
OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors
03/01/2018DOWNLOAD -
OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases
19/12/2017DOWNLOAD -
OSE Immunotherapeutics Receives a Grant from French Government Program “Fonds Unique Interministériel” to Explore New Cytotoxic Antibodies – Company’s Monoclonal Antibody, OSE-703, to be Significant Focus of Research
14/12/2017DOWNLOAD -
OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
07/12/2017DOWNLOAD -
OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
19/10/2017DOWNLOAD -
OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment
02/10/2017DOWNLOAD -
OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells
28/09/2017DOWNLOAD -
Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
26/09/2017DOWNLOAD -
OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio
07/09/2017DOWNLOAD -
OSE Immunotherapeutics Partners with Oncology Physician Network GERCOR to Conduct a Combination Phase 2 Trial of Tedopi® for Pancreatic Cancer
06/09/2017DOWNLOAD -
OSE Immunotherapeutics Announces Presentation at The 19th Annual Rodman & Renshaw Global Investment Conference, In New York City, September 10-12, 2017
31/08/2017DOWNLOAD -
OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)
19/07/2017DOWNLOAD -
OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer
23/06/2017DOWNLOAD -
OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
21/06/2017DOWNLOAD -
OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases
15/06/2017DOWNLOAD -
OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders
14/06/2017DOWNLOAD -
OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York Focused on Company’s Cytotoxic Monoclonal Antibody OSE-703 targeting IL-7R to treat cancer
12/06/2017DOWNLOAD -
Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist
23/05/2017DOWNLOAD -
OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists
22/05/2017DOWNLOAD -
OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum
18/05/2017DOWNLOAD -
OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress”, London, May 15-16, 2017
15/05/2017DOWNLOAD -
OSE Immunotherapeutics Presented New Data at AACR Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Anti-tumoral Potent T Memory Response
05/04/2017DOWNLOAD -
2016 Results: Significant Milestones, First Profit, More Growth to Come
28/03/2017DOWNLOAD -
OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) at the 24th Molecular Med TRI-CON 2017 Meeting
21/02/2017DOWNLOAD -
OSE Immunotherapeutics Announces that the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer
24/01/2017DOWNLOAD -
OSE Immunotherapeutics to present at Biotech Showcase™ 2017 Conference
04/01/2017DOWNLOAD -
OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7
28/12/2016DOWNLOAD -
OSE Immunotherapeutics appoints Dr. Frédérique Corallo, as Chief Medical Officer, Immunology
28/11/2016DOWNLOAD -
OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology
28/11/2016DOWNLOAD -
Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases
15/11/2016DOWNLOAD -
OSE Immunotherapeutics Awarded First Prize and “Listed Company” Prize as part of 2016 Deloitte In Extenso Technology Fast 50 Ouest
15/11/2016DOWNLOAD -
OSE Immunotherapeutics to present at 2016 MedStart Up Days, New York City, October 27th & 28th, 2016
24/10/2016DOWNLOAD -
OSE Immunotherapeutics to present the preclinical data of its new checkpoint inhibitor Effi-DEM on SIRP-α/CD47 strategic pathway at the 2016 Immune Checkpoint Inhibitors Conference
04/10/2016DOWNLOAD -
OSE Immunotherapeutics to present Atalante 1, the registration clinical trial of Tedopi®, ongoing in the U.S. and in Europe,
20/09/2016DOWNLOAD -
OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director
15/09/2016DOWNLOAD -
OSE Immunotherapeutics Reports on First-Half 2016 Positive Financial Results Driven by Key Clinical Milestones
08/09/2016DOWNLOAD -
OSE Immunotherapeutics will present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York City, September 11-13, 2016
30/08/2016DOWNLOAD -
OSE Immunotherapeutics presents new preclinical efficacy results with Effi-DEM, a new generation checkpoint inhibitor, at the “European Association for Cancer Research” (EACR) Congress – (Manchester, 9-12 July 2016)
12/07/2016DOWNLOAD -
OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation in autoimmune diseases
05/07/2016DOWNLOAD -
OSE Immunotherapeutics presents significant preclinical efficacy results for Effi-7, an antagonist of the IL-7 receptor
27/06/2016DOWNLOAD -
OSE Immunotherapeutics presents significant preclinical results for new generation checkpoint inhibitor, Effi-DEM
20/06/2016DOWNLOAD -
Publication of the 2015 Reference Document
09/06/2016DOWNLOAD -
OSE Pharma and Effimune shareholders approve merger to create OSE Immunotherapeutics
31/05/2016DOWNLOAD -
Launch of a non-interventional study in hepatocellular carcinoma
19/05/2016DOWNLOAD -
Dominique Costantini, Co-Founder of OSE Pharma, invited to “Bpifrance Inno Génération”
18/05/2016DOWNLOAD -
Presentation of the future entity OSE Immunotherapeutics at the 2nd « Annual Immuno-Oncology: BD&L and Investment Forum »
12/05/2016DOWNLOAD -
Effimune and OSE Pharma announce the online publication of Preclinical efficacy data for FR104 in a renal allograft model in the « Journal of the American Society of Nephrology »
11/05/2016DOWNLOAD -
Availability of preparatory documents for the combined General Meeting of May 31, 2016
27/04/2016DOWNLOAD -
OSE Pharma and Effimune announce the signing of the Merger Treaty to create OSE Immunotherapeutics
15/04/2016DOWNLOAD -
Fifth country opens recruitment in the global pivotal Phase 3 trial of the immunotherapy Tedopi with initiation in Hungary
11/04/2016DOWNLOAD -
OSE Pharma to join workshop “Phase I: An inflection point in drug development and value generation” at BIO Europe Spring 2016
04/04/2016DOWNLOAD -
OSE Pharma to attend the Small & Midcap Event in Paris on 11 & 12 April, 2016
29/03/2016DOWNLOAD -
2015: Annual Results in line with forecasts and significant advances – 2016 outlook : further development and merger project with Effimune
21/03/2016DOWNLOAD -
First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi® for advanced Non-Small Cell Lung Cancer
22/02/2016DOWNLOAD -
OSE Pharma announces U.S. initiation of Atalante 1, the Company’s global, pivoltal Phase 3 trial for Tedopi® immunotherapy in Non-Small Cell Lung Cancer
04/02/2016DOWNLOAD -
OSE Pharma anounces initiation of its pivotal Phase 3 trial of Tedopi® in Non-Small Cell Lung Cancer
06/01/2016DOWNLOAD -
OSE Pharma announces its events for Q1 2016
05/01/2016DOWNLOAD -
OSE Pharma announces selection of 70 international clinical centers to participate in its pivotal Phase 3 trial of Tedopi® for patients diagnosed with advanced non-small cell lung cancer (NSCLC)
23/12/2015DOWNLOAD -
OSE Pharma to participate to Biotech Showcase™ during JP Morgan Healthcare Conference San Francisco – January 11-13, 2016
14/12/2015DOWNLOAD -
OSE Pharma admitted to Long-Only Deferred Settlement Service
07/12/2015DOWNLOAD -
OSE Pharma receives positive opinion from several European countries to start pivotal Phase 3 trial of Tedopi®
02/11/2015DOWNLOAD -
OSE Pharma successfully completes the manufacturing of the clinical batches for its pivotal Phase 3 clinical trial with Tedopi®
19/10/2015DOWNLOAD -
OSE Pharma participe au Large & Midcap Event à Paris les 7 et 8 octobre 2015
29/09/2015DOWNLOAD -
OSE Pharma intègre les indices CAC® Small, CAC® Mid & Small et CAC® All-Tradable
16/09/2015DOWNLOAD -
OSE Pharma sera à BioPharm America les 15 et 16 septembre 2015 à Boston, Etats-Unis
14/09/2015DOWNLOAD -
OSE Pharma dévoile des résultats cliniques et immunologiques de son étude de Phase 2 chez les patients avec métastases cérébrales traités avec Tedopi® lors de la Conférence Mondiale sur le Cancer du Poumon à Denver aux Etats Unis.
09/09/2015DOWNLOAD -
OSE Pharma annonce une première étape dans le lancement de son étude de phase 3 dans le cancer du poumon : Constitution de son comité de pilotage
01/09/2015DOWNLOAD -
Présentation des résultats cliniques de Tedopi pour des patients atteints de métastases cérébrales liées à un cancer du poumon lors de la 16ème Conférence Mondiale sur le Cancer du Poumon
23/07/2015DOWNLOAD -
Résultats du vote de l’Assemblée Générale Mixte du 23 juin 2015
23/06/2015DOWNLOAD -
Mise à disposition du Document de Référence 2014
18/06/2015DOWNLOAD -
OSE Pharma participe aux « French Life Science Days » les 17 et 18 juin 2015 à New York
15/06/2015DOWNLOAD -
OSE Pharma sera présente à BIO International Convention du 15 au 18 juin 2015 à Philadelphie
08/06/2015DOWNLOAD -
Mise à disposition des documents préparatoire à l’AGM du 23 juin 2015
02/06/2015DOWNLOAD -
OSE Pharma signe son premier accord d’exploitation pour Tedopi® avec les laboratoires RAFA
11/05/2015DOWNLOAD -
Mise à disposition du Rapport Financier Annuel 2014
24/04/2015DOWNLOAD -
OSE Pharma acteur de l’équipe de France des biotechnologies médicales
17/04/2015DOWNLOAD -
Très large succès de l’introduction en Bourse d’OSE Pharma 30 mars : 1er jour de cotation
30/03/2015DOWNLOAD -
OSE Pharma lance son introduction en bourse
09/03/2015DOWNLOAD -
Enregistrement du document de base
17/09/2014DOWNLOAD -
Tedopi®, un nouvel espoir dans l’immunothérapie du cancer du poumon
12/09/2014DOWNLOAD -
OSE Pharma lève 3,2 M€
29/07/2014DOWNLOAD -
Protocole d’essai clinique de phase 3 pour Tedopi® accepté par la FDA et l’EMA
23/06/2014DOWNLOAD -
OSE Pharma acquiert les actifs de Texopi®, les droits mondiaux et du savoir-faire (en anglais)
07/04/2014DOWNLOAD -
OSE Pharma renforce son Conseil d’Administration (en anglais)
12/11/2013DOWNLOAD -
Nomination du Professeur Fridman en tant que Président du Comité scientifique (en anglais)
12/11/2013DOWNLOAD -
OSE PHARMA annonce l’obtention d’un financement d’OSEO/BPIFrance pour son immunothérapie du cancer en phase 3 (en anglais)
04/06/2013DOWNLOAD -
Premier brevet européen pour OSE PHARMA (en anglais)
31/01/2013DOWNLOAD -
OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE® (Berlin, 6-8 November 2017)
-
OSE Pharma to attend BIO-Europe 2015 The conference will take place on November 2-4 in Munich, Germany
DOWNLOAD -
OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress
DOWNLOAD